Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2023-12-13 Report Publication Anno…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists future dates for various corporate events, specifically mentioning 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, but an announcement detailing the schedule for future report publications and meetings. Since it announces the publication dates of reports, the most appropriate classification is Report Publication Announcement (RPA). It is short and serves as a schedule announcement.
2023-12-13 English
ArcticZymes Technologies ASA to present at SEB Healthcare Seminar 2023
Investor Presentation Classification · 98% confidence The document is titled 'SEB Healthcare Seminar' and features a CEO presentation ('CEO Michael Akoh') covering company overview, market analysis, product pipeline (SAN), strategic focus, and financial performance highlights. It is structured like a slide deck presentation intended for investors or analysts, rather than a formal regulatory filing (like 10-K, IR, or ER). This format strongly aligns with an Investor Presentation (IP). The length (4022 chars) is typical for a presentation summary or the presentation itself, not a short announcement (RPA/RNS).
2023-11-23 English
ArcticZymes Technologies ASA to present at SEB Healthcare Seminar 2023
Report Publication Announcement Classification · 99% confidence The document is very short (581 characters) and announces that ArcticZymes Technologies ASA will present at the SEB Healthcare Seminar 2023 today, November 23, 2023. Crucially, it states, 'Please find the presentation enclosed.' This indicates the document itself is an announcement about an upcoming presentation/event, not the presentation material (IP) or a formal regulatory filing. Since the document is announcing the availability of presentation material for an event, it aligns best with the 'Report Publication Announcement' (RPA) category, as it is announcing the release/availability of associated materials for an event, even though the event is a seminar presentation rather than a formal financial report. It is not a formal AGM, Earnings Release, or Director's Dealing. Given the context of presenting at a seminar, RPA is the most fitting category for the announcement itself.
2023-11-23 English
Long-Term Incentive Plan - grant of share options to primary insider
Director's Dealing Classification · 100% confidence The document is titled "Notification and public disclosure of transactions by primary insider" and details a transaction involving a CEO (Michael Akoh) of ArcticZymes Technologies ASA. Specifically, it reports the 'Award of options' under a share option program. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly matches the definition for Director's Dealing (DIRS). Although it involves options, the core function is reporting insider transaction activity.
2023-11-03 English
Long-Term Incentive Plan - grant of share options to primary insider
Director's Dealing Classification · 98% confidence The document explicitly announces the grant of share options to the CEO (a primary insider) under the Long-Term Incentive Plan. This action involves the personal share transactions of a director/executive. According to the definitions, 'Director's Dealing (Code: DIRS)' covers the 'Report of personal share transactions by company directors and executives (insider trades)'. Although it involves options, the core event is the insider transaction/grant notification.
2023-11-03 English
Long-Term Incentive Plan - grant of share options to primary insider
Remuneration Information Classification · 99% confidence The document explicitly details the grant of 200,000 share options to the CEO (a primary insider) under the Long-Term Incentive Plan. This action involves the transaction of shares/options by an executive. This aligns directly with the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). Although it relates to remuneration guidelines (DEF 14A), the core action described is the transaction itself, making DIRS the most precise fit. The document length is short, but it is a direct report of the transaction, not an announcement of a report's publication.
2023-11-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.